Match the claim to the product
Ask whether a study tested the medicine being offered to you. Was it a pill or a shot? Was it used for the same health problem? A medicine name alone does not answer those questions.
FDA—the Food and Drug Administration—is the agency for reviewing drug products.
As of September 2026, FDA has approved specific semaglutide products as pills or shots for specific uses. Those approvals do not cover every medicine made with semaglutide.
Ask what happened in people
When someone cites a study, ask who took part, what they received and what was measured. Ask how long the observation lasted. Ask whether it studied people or only a laboratory idea.
Ask for the study to read later. Ask the person treating you what the study’s findings mean for your care. A link alone does not answer that question.
Keep reports and causes separate
An adverse event is a reported, unwanted experience that occurs while a medical product is being used.
FDA’s September 2026 warning is that a problem report, on its own, cannot prove the medicine caused that problem. Report totals also cannot show how common a problem is.
Discuss the reports with the person treating you. Do not use the number of reports to guess your own chance of having the problem.
What an advisory meeting can tell you
An advisory committee is a group of people who advise FDA.
FDA keeps a list of extra raw ingredients that pharmacies may use to make medicines to order under one part of federal law. The list is one legal route for using an ingredient; other routes have their own conditions.
As of September 2026, a committee vote does not add an ingredient to that FDA list. FDA must first propose a rule, invite people to comment and complete its decision about changing the list.
A headline about a meeting is not enough. Ask the person writing your prescription which current rule allows the ingredient in your medicine. Ask to see that rule.
Ask for the uncertainty in plain words
A useful explanation includes what the evidence cannot answer. Ask what remains unknown for the exact product. Ask how that uncertainty affects the options being discussed.